Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato

Translated title of the contribution: Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy

Carlos Aguiar, Eduardo Alegría, Ricardo C. Bonnadonna, Alberico L. Catapano, Francesco Consentido, Moses Elisaf, Michel Farnier, Jean Fierrières, Pasquale Perronre Filardi, Nicolae Hancu, Meral Kayikcioglu, Alberto Mello e Silva, Jesús Millán, Zeljko Reiner, Lale Tokgozoglu, Paul Valensi, Margas Viigimaa, Michal Vrablik, Alberto Zambón, José Luis ZamoranoRoberto Ferrari, Mariano Blasco, Ángel Brea, Ángel Díaz, Pedro Gonzáles Santos, Antonio Hernández Mijares, Teresa Mantilla, Juan Pedro-Botet, Xavier Pintó

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

LDLc levels are associated with increase of cardiovascular risk, and statins are currently used for their control. Nevertheless, a despite of LDLc levels at goal, a residual risk is persistent, commonly associated with persistent lipids modifications (high triglycerides and low HDLc). So, it is necessary to evaluate triglycerides and HDL to assessment cardiovascular risk. Clinical data are consistent with efficacy and safety of combination therapy with statin and other lipid lowering drugs, for instance fenofibrate. Patients with hipertriglyceridemia and low HDLc are the group with most potential improve. In that patients with atherogenic dyslipidemia, the target for therapeutic objectives related with non-HDL-cholesterol is a priority, because non-HDL-cholesterol is considered as a more accuracy measure to assessment cardiovascular risk.

Translated title of the contributionConsensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy
Original languageSpanish
Pages (from-to)87-93
Number of pages7
JournalClinica e Investigacion en Arteriosclerosis
Volume28
Issue number2
DOIs
Publication statusPublished - 1 Mar 2016

Keywords

  • Atherogenic dyslipidemia
  • Lipid lowering combination therapy
  • Statine-fenofibrate association

Fingerprint

Dive into the research topics of 'Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy'. Together they form a unique fingerprint.

Cite this